ResearcherAkita UniversityActive in the last 2 years

Hiroyuki Shibata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3581-3506; OpenAlex author ID A5114375607. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 2 papers

Papers 2

Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor. Last author DOI 10.1093/jjco/hyad157 ↗
Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: stu… Co-author DOI 10.1186/s12885-024-11973-9 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Risa Akahira · 1 shared paper, 2024 · strength 0.23
- Paper Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP… DOI 10.1093/jjco/hyad157 ↗
Atsushi Satō · 1 shared paper, 2024 · strength 0.21
- Paper Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patie… DOI 10.1186/s12885-024-11973-9 ↗
Kenji Amagai · 1 shared paper, 2024 · strength 0.21
- Paper Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patie… DOI 10.1186/s12885-024-11973-9 ↗
Hiroo Imai · 1 shared paper, 2024 · strength 0.21
- Paper Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patie… DOI 10.1186/s12885-024-11973-9 ↗
Chikashi Ishioka · 1 shared paper, 2024 · strength 0.21
- Paper Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patie… DOI 10.1186/s12885-024-11973-9 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.